BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
PRKCA
,
T cell differentiation
,
Ischemia
,
Lymphocyte
,
Nosology
,
Lovastatin
,
rs2230926
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
auranofin
Summary
General Info
Curated Studies
Most Correlated Studies
B-cell lymphoma cell lines treated by 92 FDA approved compounds - a timecourse
Drug Matrix In Vivo Toxicogenomic Study - Rat Kidney [Codelink]
Explore Curated Studies Results
Literature
Most Relevant Literature
In vitro antifungal and antibiofilm activities of auranofin against itraconazole-resistant Aspergill…
Auranofin-Loaded Chitosan Nanoparticles Demonstrate Potency against Triple-Negative Breast Cancer.
Combined Auranofin and Celecoxib Suppresses the Local Progression and Pulmonary Metastases of Osteos…
Inhibition of selenoprotein synthesis is not the mechanism by which auranofin inhibits growth of Clo…
Auranofin inhibits the occurrence of colorectal cancer by promoting mTOR-dependent autophagy and inh…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Auranofin PK Following Oral Dose Administration
Auranofin for Giardia Protozoa
Oral Auranofin for Reduction of Latent Viral Reservoir in Patients With HIV Infection
Auranofin and Sirolimus in Treating Participants With Ovarian Cancer
Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian T…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ